This study investigates solid tumors. It looks at how an investigational medication combined with hydroxychloroquine and either 5-fluorouracil or gemcitabine affects these tumors.
The study evaluates the overall response rate, progression-free survival, and safety of the treatment. It focuses on how the combination works in managing advanced solid tumors.
- Who can participate: Adults 18 and older with advanced solid tumors that have not responded to standard treatments may participate. Participants must meet specific health criteria and have certain types of cancer, such as colorectal, pancreatic, or gastroesophageal.
- Study details: Participants will receive an investigational medication with hydroxychloroquine and either 5-fluorouracil or gemcitabine.